BioCryst Pharmaceuticals
BCRX
272 hedge funds and large institutions have $1.66B invested in BioCryst Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 91 increasing their positions, 101 reducing their positions, and 58 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
55% more call options, than puts
Call options by funds: $12M | Put options by funds: $7.76M
12% more capital invested
Capital invested by funds: $1.48B → $1.66B (+$181M)
8.32% more ownership
Funds ownership: 92.5% → 100.82% (+8.3%)
10% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 101
5% less funds holding
Funds holding: 286 → 272 (-14)
16% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$114M |
| 2 |
Janus Henderson Group
London,
|
+$52.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$22.9M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$20.4M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$41.5M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$37.3M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$27.5M |
| 4 |
Morgan Stanley
New York
|
-$25M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$19.8M |
BCRX Hedge Fund Activity: Q4 2025 in Review
272 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2025, worth a combined $1.66B — up 12% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of BCRX and 49 opened new positions — a net loss of 9 holders — while 101 trimmed existing stakes and 91 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $114M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $41.5M sold.
- 272 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2025, down from 286 in Q3 2025.
- Funds reported $1.66B of BioCryst Pharmaceuticals stock for Q4 2025, up 12% quarter-over-quarter.
- 49 funds opened new BioCryst Pharmaceuticals positions in Q4 2025 and 58 closed out, a net change of -9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2025 was RA Capital Management, an estimated $114M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2025 was Alkeon Capital Management, an estimated $41.5M sold.
Based on aggregated 13F filings for Q4 2025.